Informations

Innovations in Drug Development ROS1 For patients with ROS1-positive advanced NSCLC, crizotinib was previously the standard treatment. However, its efficacy, particularly in terms of progression-free survival (PFS), was limited to…

Abstract ID: 117TiP Title: Safety and Efficacy of Reduced-Port Laparoscopic Surgery for Colon and Upper Rectal Cancer: A Multicenter, Prospective, Randomized Phase III Study Background Radical resection remains the cornerstone…

Abstract ID: 119TiP Title: A Randomized, Controlled, Multicenter Phase III Study of IBI310 (Anti-CTLA-4 Antibody) Plus Sintilimab (Anti-PD-1 Antibody) as Neoadjuvant Therapy for Resectable MSI-H/dMMR Colon Cancer Presenter: Professor Ruihua…

Key Oncogenic Targets in Focus FGFR2 Approximately 3%–5% of gastric cancer patients exhibit FGFR2 overexpression or amplification, which is associated with tumor dissemination and poor prognosis. Studies on FGFR2 inhibitors…

Progress in First-Line Treatment of Advanced Gastric Cancer Targeted Therapy + Chemotherapy ± Immunotherapy: Advances and Breakthroughs CLDN18.2 The SPOTLIGHT and GLOW studies are global, multicenter, randomized, double-blind, placebo-controlled phase…

Editor’s Note: According to the latest data released by the National Cancer Center, over 350,000 new cases of gastric cancer are diagnosed annually in China, making it the fifth most…

Advances in Neoadjuvant Therapy Neoadjuvant therapy has become a critical strategy for locally advanced gastric cancer (LAGC), with increasing emphasis on the role of immunotherapy and targeted therapy. 1. Immunotherapy…

Defining BCR and Advancements in NHT Therapy Biochemical recurrence (BCR) in prostate cancer refers to a rise in PSA levels following radical treatment without evidence of imaging-detectable metastasis. BCR signifies…